|
|
Article: Following Stock Rise, OxiGene Private Placement Raises $15M.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Associate Managing Editor
Less than one month ago, OxiGene Inc.'s stock sat below $2 per share. Its 2003 high to that point was a Jan. 13 closing of $2.64.
But in the past month, riding its developing pipeline and a positive swell of biotechnology cancer interest, its stock has taken off. OxiGene on Tuesday said it had agreements with three institutional investors to sell 1.5 million shares at $10 per share, raising $15 million to fund its pipeline.
"The catalyst behind the financing is our lead compound, CA4P, which has advanced into a Phase II clinical trial," said Fred Driscoll, president and CEO of Watertown, Mass.-based OxiGene. "This ...
Related newspaper, magazine, and journal articles:
|
|
Article: FOLLOWING STOCK RISE, OXIGENE PRIVATE PLACEMENT RAISES ...
BIOWORLD Today;
June 11, 2003 ;
700+ words
... ... events, might help explain OxiGene's fast stock rise. In ... oxygen and nutrients. (See BioWorld Today, May 20, 2003.) Quickly ... companies in particular. (See BioWorld Today, June 3, 2003.) OxiGene's rise has gone like this ...
|
|